Name: OECD_SIDS / SUBSTANCE : chlorocyclohexane / chlorocyclohexane / 542-18-7 Fri,
16 Dec 2022, 15:39:03+0900 /Legal entity owner: National Institute of Health Sciences
Printing date: 2022-12-16T15:39:03.352+09:00

iTable of Contents
0/0 ............................................................................................................................. 1
National Institute of Health Science ..................................................................... 2
chlorocyclohexane ............................................................................................... 3
1 General information .................................................................................. 3
1.1 Identification ................................................................................. 3
Identification ............................................................................... 3
Identification ...................................................................... 3
1.10 Assessment approach (assessment entities) ................................. 4
Assessment approach (assessment entities) ................................ 4
7 Toxicological information ......................................................................... 5
7.2 Acute Toxicity ............................................................................... 5
7.2.1 Acute toxicity: oral .............................................................. 5
Acute toxicity: oral.001 ........................................................ 5
7.5 Repeated dose toxicity ................................................................... 9
7.5.1 Repeated dose toxicity: oral ................................................. 9
Repeated dose toxicity: oral.001 ........................................... 9
7.6 Genetic toxicity ............................................................................ 17
7.6.1 Genetic toxicity in vitro ...................................................... 17
Genetic toxicity in vitro.001 ................................................ 17
Genetic toxicity in vitro.002 ................................................ 21
7.8 Toxicity to reproduction ............................................................... 25
7.8.1 Toxicity to reproduction ..................................................... 25
Toxicity to reproduction.001 ............................................... 25
References ................................................................................................................ 33
Reference Substances ...................................................................................... 33
chlorocyclohexane ..................................................................................... 33
Test Materials .................................................................................................. 35
chlorocyclohexane / 542-18-7 / 208-806-6 .................................................. 35
Literatures ....................................................................................................... 36
A combined repeated-dose/reproductive-developmental toxicity study ofchlorocyclohexane by oral administration in rats. ........................................ 36
In Vitro Chromosomal Aberration Test of Chlorocyclohexane on Cultured
Chinese Hamster Cells .............................................................................. 37
Reverse Mutation Test of chlorocyclohexane on Bacteria. ............................ 38
Single Dose Oral Toxicity Test of Chlorocyclohexane in Rats ........................ 39
Legal Entities ................................................................................................... 40
National Institute of Health Sciences .......................................................... 40ii

DOSSIER:UUID: 0
Dossier UUID:
Author:Date: 2022-12-16T15:39:03.199+09:00
Remarks:

Dossier header
Dossier submission type
Name
OECD SIDS
Versioncore 7.0
Name (given by user)

Dossier subject
Dossier subject
chlorocyclohexane / chlorocyclohexane / 542-18-7
Public nameSubmitting legal entity
National Institute of Health Science
Dossier creation date/time
Fri, 16 Dec 2022, 15:39:03+0900
Used in category

1

LEGAL_ENTITY: National Institute of Health
Science
UUID: f51e7b54-9211-4863-90ce-fcf8a155d647
Dossier UUID:
Author:Date: 2022-11-07T16:24:02.822+09:00
Remarks:

General information
Legal entity nameNational Institute of Health Science2

chlorocyclohexane
General information
Identification
Identification
SUBSTANCE: chlorocyclohexane

UUID: IUC5-cd10453c-72f2-45d4-a87e-fc2882f22d3b
Dossier UUID:
Author:Date: 2022-12-16T15:38:53.673+09:00
Remarks:
Substance namechlorocyclohexane
Legal entity
National Institute of Health Sciences / Kawasaki / Japan

Identification of substance
Reference substancechlorocyclohexane / chlorocyclohexane / 542-18-7 / 208-806-6
EC number

EC name208-806-6

EC Inventory

CAS number

CAS name542-18-7
IUPAC namechlorocyclohexane

Role in the supply chain
Manufacturer
false
Importer
false
Only representativefalse
Downstream user
false

3

Assessment approach (assessment entities)
FIXED_RECORD: Assessment approach
UUID: 0e786433-e052-36ba-9957-1546f3cee548
Dossier UUID:
Author:Date: 2017-01-04T16:41:51.000+09:00
Remarks:4

Toxicological information
Acute Toxicity
Acute toxicity: oral
ENDPOINT_STUDY_RECORD: Acute toxicity: oral.001

UUID: IUC5-6f52b438-c5b8-41b0-b587-ae524ef28122
Dossier UUID:
Author:Date: 2022-12-12T14:33:55.039+09:00
Remarks:

Administrative data
Endpoint
acute toxicity: oral
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source
Reference
Single Dose Oral Toxicity Test of Chlorocyclohexane in Rats / MHLW (Ministry of Health, Labour andWelfare), Japan / study report
Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
5Guideline
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Deviationsno
GLP compliance
yes
Test type
standard acute method
Limit test
yes

Test material
Test material information
chlorocyclohexane / 542-18-7 / 208-806-6
Specific details on test material used for the study- Name of test material (as cited in study report): Chlorocyclohexane- CAS No.: 542-18-7- Molecular weight: 118.61- Lot No.: 5C1114- Purity: 99.7%- Supplier: Junsei Chemical Co., Ltd.
- Vapor pressure: 6.73 mmHg (25°C)- Vapor density : 4.12 (air = 1)
- Boiling point : 142°C- Melting point: -44°C- Flash point: °C- Specific gravity: 1.004 (20/4°C)- Solubility: Insoluble in water and miscible by organic solvents as the alcohol and ether et al.
- Odor: Characteristic odor
- Physical state: Slightly pale yellow from colorless liquid- Storage condition of test material: Dark and sealed in refrigerator (2.8 – 8.4°C)

Test animals
Speciesratcommon species
Strain
Crj: CD(SD)rat
Sex
femaleAdministration / exposure
Route of administration
oral: gavage
Vehicleolive oil
6

Details on oral exposure
VEHICLE- Concentration in vehicle: 60 and 400 mg/ml.MAXIMUM DOSE VOLUME APPLIED: 5 ml/kg b
.w.
Doses
300 mg/kg bw (first and second administration)2000 mg/kg bw (third and fourth administration)
No. of animals per sex per doseFirst and second administration (first purchase): 3 animals and 3 animals (animal ID No. 50101 – 501
03 and 60101 - 60103) /female/300 mg/kg doseThird and fourth administration (second purchase): 3 animals and 3 animals (animal ID No. 70101 –
70103 and 80101 - 80103) /female/2000 mg/kg dose
Control animals
noDetails on study design- Duration of observation period following administration: 14 days
- Frequency of observations: Before dosing, Day 1 (day of administration):10, and 30 minutes and 1, 3,
and 6 hrs after administration. After day 2: once a day- Frequency of weighing: Days 1 (before administration), 4, 8 and 15- Necropsy of survivors performed: Yes
Statistics
No

Results and discussion
Preliminary study
Dose levels were determined by the Globally Harmonized Classification System (GHS) (mg/kg b.w.).
Mortality was not observed in each first and second administrations of 300 mg/kg groups and ineach third and fourth administrations of 2000 mg/kg groups.
Effect levels
Key result
false
Sex
female
Dose descriptor
LD50
Effect level>

2000

Mortality
No deaths were observed from first to fourth administration.
Clinical signs
other: No changes related to the test substance were observed from first to forth administration.
Gross pathology
No changes related to the test substance were observed from first to fourth administration.
7

Other findings- Organ weights: No data- Histopathology: No data- Potential target organs: Not identified- Other ob
servations: No data

Applicant's summary and conclusion
Conclusions
The LD50 value was more than 2000 mg/kg bw for females.
GHS classification was classified in Category 5 (>2000 – 5000 mg/kg b.w.).

8

Repeated dose toxicity
Repeated dose toxicity: oral
ENDPOINT_STUDY_RECORD: Repeated dose toxicity: oral.001

UUID: IUC5-32931199-101f-41ea-aa8c-9e2425253f75
Dossier UUID:
Author:Date: 2022-12-16T15:36:32.251+09:00
Remarks:

Administrative data
Endpoint
short-term repeated dose toxicity: oral combined repeated dose and reproduction / developmental
screening
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition
Cross-reference
Reason / purpose for cross-reference
reference to same study
Remarks
7.8.1 Toxicity to reproduction: Toxicity to reproduction.001

Data source
Reference
A combined repeated-dose/reproductive-developmental toxicity study of chlorocyclohexane by oral
admi / MHLW (Ministry of Health, Labour and Welfare), Japan / study report9Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction /Developmental Toxicity Screening Test)
Deviationsno
GLP compliance
yes
Limit test
no

Test material
Test material information
chlorocyclohexane / 542-18-7 / 208-806-6
Specific details on test material used for the study- Name of test material (as cited in study report): Chlorocyclohexane- CAS No.: 542-18-7- Molecular weight: 118.60- Lot No.: 5C1114- Purity: 99.7%- Supplier: Junsei Chemical Co., Ltd.
- Vapor pressure: 6.73 mmHg (25°C)- Vapor density : 4.12 (air = 1)
- Boiling point : 142°C- Melting point: -44°C- Flash point: 29°C
- Specific gravity: 1.004 (20/4°C)- Solubility: Insoluble in water and miscible with organic solvents such as alcohol and ether etc.
- Odor: Peculiar odor
- Physical state: Colorless liquid to slightly pale yellow- Storage condition of test material: Dark and sealed in refrigerator (2.8 – 8.4°C)

Test animals
Speciesratcommon rodent species
Strain
Crj: CD(SD)rat
Sexmale/female
10Details on test animals or test system and environmental conditions
TEST ANIMALS- Source: Atsugi Breeding Center, Charles River Laboratories Japan, Inc.
- Age at study initiation: 9 weeks of age- Weight at study initiation: 325-386 g for males and 193-231 g for females- Housing: bracket-type metallic wire-mesh cages/males and females excluding gestation and lactation periods (W 195 × D 325 × H 180 mm),and polycarbonate cage during gestation and lactation periods/females (W 265 × D 426 × H 200 mm)- Water (e.g. ad libitum):ad libitum- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS- Temperature (°C): 21.4 to 23.7°C- Humidity (%): 48.8 to 65.0%- Air changes (per hr): 6 to 20 times per hour
- Photoperiod (hrs dark / hrs light):12-hour lighting per day

Administration / exposure
Route of administration
oral: gavage
Vehicleolive oil
Details on oral exposure
PREPARATION OF DOSING SOLUTIONS: Test substance was dissolved in olive oil for injection.
VEHICLE- Justification for use and choice of vehicle: No data
- Amount of vehicle (if gavage): 5 ml/kg bw- Lot/batch no. (if required): No data
- Dosing volume: 5 mL/kg- Stability (test solutions): For 8 days
- Storage condition of test solution: Stored in a dark place at room temperature
Analytical verification of doses or concentrations
yes
Details on analytical verification of doses or concentrations
Test suspensions at each concentration of initial and final preparations were analyzed by the GC met
hod at Mitsubishi Safety Institute Ltd. Results showed that the concentration of the test article in eachsuspension was 95.0 to 106.2% of the nominal concentration and both values were within the acc
eptable range (concentration: percentage of the nominal concentration, 100 ± 10%)Duration of treatment / exposure(P) Males: 42 days including 14 days pre-mating and mating periods(P) Females: Days including 14 days pre-mating, mating and gestation periods and the days until day
4 of lactation
Frequency of treatment
Daily: 7 times / week
Doses / concentrations
Remarks
Doses / Concentrations:
0 (vehicle), 10, 60 and 300 mg/kg bw/day
Basis:
actual ingested
11No. of animals per sex per dose
12 females/dose (0, 10, 60, 300 mg/kg), 7, 12, 12, 7 males of 0, 10, 60, 300 mg/kg, respectively, 5
males and 5 females at 0 and 300 mg/kg bw/day (recovery group)
Control animals
yes, concurrent vehicle
Details on study design- Dose selection rationale: A preliminary study was conducted to determine the doses to be employed.
Three males and three female SD rats receiving 0, 30, 100, 300, and 1000 mg/kg groups of the substa
nce were administered for 14 days. As a result, death or moribundity was observed in all males andfemales receiving 1000 mg/kg groups. Salivation and increases in absolute and relative adrenal
weights were observed in females receiving 300 mg/kg group. No clear changes related to the test
substance were observed in males receiving 300 mg/kg group. Therefore, the high dose was set at
300 mg/kg/day, and the middle and low dose were set at 60 and 10 mg/kg/day using common ratio
5. Vehicle control groups were set using olive oil only.

Examinations
Observations and examinations performed and frequency
CAGE SIDE OBSERVATIONS: Yes- Time schedule:
Males and females: once before the start of administration, during the administration period, andduring the recovery period
DETAILED CLINICAL OBSERVATIONS: Yes- Time schedule:
Males: once before the start of administration, once every week until Week 6 during the administration
Females: once before the start of administration, once every week until Week 6 during the admi
nistration and once during the lactation period.
No observation performed during the recovery period because no observed clinical changes during
the administration period.
BODY WEIGHT: Yes- Time schedule for examinations:
Males in the main and recovery groups were weighed on Day 1, 8, 15, 22, 29, 36, 42, and 43 of administration, and males of recovery groups were weighed on Day 50 and 56. Female satellite groups
were weighted same frequencies to male recovery groups. Females in the main groups were weighedon Day 1, 8 and 15 of administration and copulated females were weighed on Day 0, 7, 14 and 20 of
gestation, and days 0 and 4 of lactation.
FOOD CONSUMPTION : Yes- Food consumption (g/day/rat) for each animal determined from the difference of the of the previous
day's feeding amount: Yes
Measurement of food consumption was conducted on all animals at the following frequencies:
Males in the main and recovery groups on Day 1-8, 8-15, 15-22, 22-29, 29-36, 36-38, 43-50, and 50-52.
Female satellite groups on Day 1-8, 8-15, 15-22, 22-29, 29-36, 36-42, 43-50, and 50-56. Females in themain group on Day 1-8, 8-15, 22-29, 29-36, 36-38, 43-50, and 50-52.
FOOD INTAKE: No
HAEMATOLOGY: Yes- Time schedule for collection of blood: On the day after the final day of administration and on the
final day of the recovery period- Anaesthetic used for blood collection: Yes- Animals fasted: Yes- How many animals: 5 animals/sex/group- Parameters examined red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, reticulocyte count, platelet
count, white blood cell count, differential white blood cell count, prothrombin time, activated partial
thromboplastin time12

CLINICAL CHEMISTRY: Yes- Time schedule for collection of blood: On the day after the final day of administration and on the ending day of the recovery period- Animals fasted: Yes- How many animals: 5 animals/sex/group- Parameters checked: ASAT (GOT), ALAT (GPT), γ-GT, ALP, total bilirubin, blood urea nitrogen,creatinine, glucose, total cholesterol, triglyceride, total protein, albumin, A/G ratio, calcium, inorganic
phosphorus, sodium, potassium, chloride
URINALYSIS: Yes- Time schedule for collection of urine: final week of administration (Day 38 of administration) inmales- Metabolism cages used for collection of urine: Yes- Animals fasted: Yes- How many animals: 5 animals/males/group- Parameters checked: pH, protein, glucose, ketones, bilirubin, occult blood, urobilinogen
BLOOD HORMONE: No
NEUROBEHAVIOURAL EXAMINATION: Yes- Battery of functions tested:
1) Open field observation: Aerial righting reaction, arousal, urination, defecation, posture and body
position, breathing, co-ordination movement, gait, tremor, clonic convulsion, tonic convulsion,
stereotypy, and bizarre behavior.
2) Manipulative Test: Approach response, touch response, auditory response, tail pinch response, andaerial righting reflex3) Measurement of Grip Strength: Grip strength of forelimb and hind limb
4) Measurement of Motor Activity.Motor activity: 10-minute intervals from 0 to 60 minutes
Sacrifice and pathology
GROSS PATHOLOGY AND ORGAN WEIGHTS：Brain, heart, liver, kidneys, adrenals, thymus, spleen,
testes, and epididymis.
HISTOPATHOLOGY: Cerebrum, pituitary, thymus, lymph nodes (including mesenteric and mandibularlymph nodes), trachea, lung, stomach, intestinal tract (duodenum, jejunum, ileum, cecum, colon,
rectum), thyroids, parathyroid, heart, liver, spleen, kidneys, adrenals, urinary bladder, testes, epididymis, seminal vesicles (including the coagulating gland), prostate (ventral lobe), ovaries, uterus, vagina,
bone marrow (one side femur), Sciatic nerve (one side femur), spinal cord, and gross abnormal sites.
Statistics
The data were analyzed for homogeneity of variance by the Bartlett test. If variances were
homogeneous, data was analyzed by one-way analysis of variance, whereas heterogenous data
was analyzed by Kruskal-Wallis ranking test. When a significant difference was observed, Dunnett’s
multiple comparison test was conducted between control and treated groups. If not homogenous,
analysis was performed using the Kruskal-Wallis ranking test. Qualitative value as the pathologicalfindings was analyzed by Wilcoxon test and Fisher’s exact test. Urinalyses data were analyzed by
Kruskal-Wallis and Dunnet’s type mean rank test. Statistical significance was set at < 5% by two-si
ded.

Results and discussion
Results of examinations
Clinical signs
effects observed, treatment-related
Mortality
mortality observed, treatment-related
Body weight and weight changes
effects observed, treatment-related
13

Food consumption and compound intake (if feeding study)no effects observed
Food efficiency
not examined
Haematological findings
no effects observed
Description (incidence and severity)
Significant increase in reticulocyte counts was observed in males receiving 300 mg/kg bw/day, but it
was not considered to be toxicological effects.
Clinical biochemistry findings
effects observed, treatment-related
Description (incidence and severity)
Significant decrease in inorganic phosphorus concentration was observed in females receiving 300
mg/kg bw/day, but it was not considered to be toxicological effects.
Urinalysis findings
no effects observed
Behaviour (functional findings)
no effects observed
Organ weight findings including organ / body weight ratios
effects observed, treatment-related
Gross pathological findings
effects observed, treatment-related
Histopathological findings: non-neoplastic
effects observed, treatment-related
Histopathological findings: neoplastic
not specified
Details on results
CLINICAL SIGNS AND MORTALITY: No animal died in any group. Salivation was observed in males and females receiving 300 mg/kg from Day 9 to the end of dosing. No abnormal changes wereobserved in both sexes with recovery animals during the recovery period.
DETAILED CLINICAL OBSERVATIONS, MANIPULATIVE TEST, GRIP STRENGTH TEST AND
LOCOMOTOR ACTIVITY MEASUREMENT: There were no changes related to the test substance in anygroup during the dosing.
BODY WEIGHT: Depression of body weight gains was observed in males and females receiving 300
mg/kg from Day 8 to 42.
ORGAN WEIGHTS: A significant increase in relative kidney weight was observed in males receiving
300 mg/kg bw/day at the end of both administration and recovery periods. HISTOPATHOLOGY: H
yaline droplet of proximal tubular epithelium in kidneys was observed in all males receiving 300 mg/
kg. Minimal hyperplasia of mucosal epithelium in urinary bladder was observed in males receiving
60 mg/kg and males and females receiving 300 mg/kg at the end of the administration. This pathological change was found in females receiving 300 mg/kg after the recovery period. Minimal cell in
filtration was present in one male and one female receiving 300 mg/kg at the end of administration and recovery periods.

Effect levels
Key result
false
14

Dose descriptor
NOAEL
Effect level10

mg/kg bw/day (actual dose received)

Sex
male
Basis for effect level
other: Effects of lesions in the hyperplasia of mucosal epithelium of urinary bladder in males receiving 60 mg/kg .
Key result
false
Dose descriptor
NOAEL
Effect level60

mg/kg bw/day (actual dose received)

Sex
femaleBasis for effect level
other: Effects of lesions in the hyperplasia of mucosal epithelium of urinary bladder in females
receiving 300 mg/kg.

Target system / organ toxicity
Key result
false
Critical effects observed
not specified

Any other information on results incl. tables
Figures and Tables (in English) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF542-18-7d.pdf

Applicant's summary and conclusion
Conclusions
Based on the effects of chlorocyclohexane on the urinary bladder, the no observed adverse effect level (NOAEL) for repeated oral dosing was determined to be 10 mg/kg bw/day in male rats and 60 mg/
kg bw/day in female rats.
Executive summary
15

A combined repeated oral dose toxicity study and reproduction/developmental toxicity screening test
was performed according to the OECD TG 422. Male and female rats (12 animals/sex/dose) wereadministered chlorocyclohexane at 0, 10, 60, and 300 mg/kg bw/day. Males were dosed for 42 days,
including a 14 day pre-mating period and subsequent mating period. Females were dosed for up to
55 days, including 14 day pre-mating, mating, and gestation periods, and the time until lactation day
4. Five out of 12 males dosed at 0 and 300 mg/kg bw/day were treated as a recovery group. In
addition, 5 females/dose 0 and 300 mg/kg bw/day groups were dosed for 42 days without mating andexamined after the recovery period. At 300 mg/kg bw/day, increased salivation and decreased bodyweight gain were observed in both sexes. Absolute and relative kidney weights increased and hyaline
droplet formation in the proximal tubular epithelium increased in males administered 300 mg/kg bw/
day. Hyperplasia of the urinary bladder mucosal epithelium was observed in males administered 60 and
300 mg/kg bw/day and in females administered 300 mg/kg bw/day. Among these changes, increased
relative kidney weight in males and hyperplasia of the urinary bladder mucosal epithelium in females
persisted after the recovery period. Based on these effects in the kidney and urinary bladder, the NOAELs
for repeated dose toxicity were determined to be 10 mg/kg bw/day and 60 mg/kg bw/day in male andfemale rats, respectively.

16Genetic toxicity
Genetic toxicity in vitro
ENDPOINT_STUDY_RECORD: Genetic toxicity in vitro.001

UUID: IUC5-6d4f5ddf-6d29-41e4-b901-cef79aa25950
Dossier UUID:
Author:Date: 2022-12-16T15:37:25.477+09:00
Remarks:

Administrative data
Endpoint
in vitro gene mutation study in bacteria Type of genotoxicity: gene mutation
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source
Reference
Reverse Mutation Test of chlorocyclohexane on Bacteria. / MHLW (Ministry of Health, Labour andWelfare), Japan / study report
Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
OECD Guideline 471 (Bacterial Reverse Mutation Assay)17

in vitro gene mutation study in bacteria
Deviations
no
Qualifieraccording to guideline
Guideline
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
Deviationsno
GLP compliance
yesType of assay
bacterial reverse mutation assay
in vitro gene mutation study in bacteria

Test material
Test material information
chlorocyclohexane / 542-18-7 / 208-806-6
Specific details on test material used for the study- Name of test material (as cited in study report): Chlorocyclohexane- CAS No.: 542-18-7- Molecular weight: 118.61- Lot No.: 5C1114- Purity: 99.7%- Supplier: Junsei Chemical Co., Ltd.
- Vapor pressure: 6.73 mmHg (25°C)- Vapor density : 4.12 (air = 1)
- Boiling point : 142°C- Melting point: -44°C- Flash point: °C- Specific gravity: 1.004 (20/4°C)- Solubility: Insoluble in water and miscible by organic solvents as the alcohol and ether et al.
- Odor: Characteristic odor
- Physical state: Slightly pale yellow from colorless liquid- Storage condition of test material: Dark and sealed in refrigerator (2.8 - 8.4°C)

MethodSpecies / strain
Species / strain / cell typeS. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2bacteria
Metabolic activation
with and without
Metabolic activation system
SD male rat liver, induced by phenobarbital and 5,6-benzoflavone
Test concentrations with justification for top dose
-S9 mix: 2.44, 4.88, 9.77, 19.5, 39.1, 78.1, 156 μg/plate (TA100, TA1535 strains),
18

9.77, 19.5, 39.1, 78.1, 156, 313 μg/plate (TA98, TA1537, WP2uvrA/pKM101 strains)+S9 mix: 9.77, 19.5, 39.1, 78.1, 156, 313 μg/plate (TA100, TA1535, TA98, TA1537 strains),
9.77, 19.5, 39.1, 78.1, 156, 313, 625 μg/plate (WP2uvrA/pKM101 strain)
Vehicle / solvent- Vehicle(s)/solvent(s) used: DMSO
Controls
Untreated negative controlsnoNegative solvent / vehicle controls
yes
True negative controlsnoPositive controls
yes
Positive control substanceother: -S9 mix: 2-(2-Furyl)-3-(5-nitro-2-furyl) acrylamide (TA 100, TA98 and WP2 uvrA/pKM101), so
dium azide (TA1535) and 9-aminoacridine hydrochloride (TA1537). +S9 mix: 2-aminoanthracene (allstrains)
Details on test system and experimental conditions
METHOD OF APPLICATION: Preincubation DURATION- Preincubation period: 20 min at 37°C - Exposure duration:48 hrs NUMBER OF PLATES: 3 NUMBER OF REPLICATIONS: 1 DETERMINATION OFCYTOTOXICITY- Method: other: growth inhibition
Evaluation criteria
In any strain(s) tested with or without S9 mix, when the mean number of revertant colonies per plateincreased twice more than that of the negative control and when the increase was shown to be dose-r
elated and reproducible, the chemical was judged mutagenic.
Statistics
No

Results and discussion
Test results
Key result
false
Species / strain
S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2bacteria
Metabolic activation
with and without
Genotoxicity
negative
Cytotoxicity / choice of top concentrations
cytotoxicity
19

Vehicle controls validity
valid
Untreated negative controls validity
not examined
Positive controls validity
valid
Additional information on results
RANGE-FINDING/SCREENING STUDIES: Concentration: 1.22, 4.88, 19.5, 78.1, 313, 1250, 5000 μg/
plate with and without S9 mix
Cytotoxic conc.: -S9 at 78.1μg/plate and higher, +S9 at 313 μg/plate and higher
Remarks on result
other: all strains/cell types tested Migrated from field 'Test system'.

Any other information on results incl. tables
Figures and Tables (in Japanese) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF542-18-7e.pdf
Tables (in English) are attachted to this document. Please download the export file to see the Tables.

Overall remarks, attachments
Overall remarks
No increase in revertant colonies was observed in the test with either the non-activation method (-S9)
or activation (+S9) method. Reverse mutation assays using microorganisms (Salmonella typhimurium,
Escherichia coli) were conducted to assess the potential of chlorocyclohexane to induce genemutations. Chlorocyclohexane did not induce gene mutations in the bacteria under the conditions of
this study. The positive control showed expected results.

Applicant's summary and conclusion
Conclusions
Chlorocyclohexane did not induce gene mutations in the in vitro bacteria test.

20

ENDPOINT_STUDY_RECORD: Genetic toxicity in vitro.002

UUID: IUC5-5c6ddd27-d102-4a29-91ea-e87ededc3b69
Dossier UUID:
Author:Date: 2022-12-16T15:38:04.901+09:00
Remarks:

Administrative data
Endpoint
in vitro cytogenicity / chromosome aberration study in mammalian cells Type of genotoxicity:
chromosome aberration
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source
Reference
In Vitro Chromosomal Aberration Test of Chlorocyclohexane on Cultured Chinese Hamster Cells /MHLW (Ministry of Health, Labour and Welfare), Japan / study report
Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
21

in vitro cytogenicity / chromosome aberration study in mammalian cells
Deviations
no
Qualifieraccording to guideline
Guideline
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
Deviationsno
GLP compliance
yesType of assay
in vitro mammalian chromosome aberration test
chromosome aberration

Test material
Test material information
chlorocyclohexane / 542-18-7 / 208-806-6
Specific details on test material used for the study- Name of test material (as cited in study report): Chlorocyclohexane- CAS No.: 542-18-7- Molecular weight: 118.61- Lot No.: 5C1114- Purity: 99.7%- Supplier: Junsei Chemical Co., Ltd.
- Vapor pressure: 6.73 mmHg (25°C)- Vapor density : 4.12 (air = 1)
- Boiling point : 142°C- Melting point: -44°C- Flash point: °C- Specific gravity: 1.004 (20/4°C)- Solubility: Insoluble in water and miscible by organic solvents as the alcohol and ether et al.
- Odor: Characteristic odor
- Physical state: Slightly pale yellow from colorless liquid- Storage condition of test material: Dark and sealed in refrigerator (2.8 - 8.4°C)

MethodTarget gene
Chromosome
Species / strain
Species / strain / cell typeother: Chinese hamster lung(CHL/IU) cells
Metabolic activation
with and without
22

Metabolic activation system
SD male rat liver, induced by phenobarbital and 5,6-benzoflavone
Test concentrations with justification for top dose
-S9 mix (short term treatment): 100, 150, 200, 250, 300, 350 ug/mL+S9 mix (short term treatment): 200, 300, 400, 450, 500 ug/mL
Continuous treatment: 150, 175, 200, 225, 275 ug/mL
Vehicle / solvent- Vehicle(s)/solvent(s) used: DMSO
Controls
Untreated negative controlsnoNegative solvent / vehicle controls
yes
True negative controlsnoPositive controls
yes
Positive control substanceother: [continuous treatment -S9]: mitomycin C; [continuous treatment +S9]: Benzo[a]pyrene
Details on test system and experimental conditions
METHOD OF APPLICATION: Exposure duration: [continuous treatment]: 24 hrs [short-term treatment]:6 hrs + 18 hr
SPINDLE INHIBITOR: Colcemid
STAIN: Giemsa stain for 20 min.
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: 200 cells / dose
DETERMINATION OF CYTOTOXICITY- Method: relative total growth
Evaluation criteria
For the evaluation of the frequencies of structural aberrations and of polyploidy induced, the following
criteria, which are usually used for chromosomal aberration testing with CHL, were employed. Ap
pearance incidence of cell with chromosomal aberrations:Negative(-): less than 5%Equivocal(±): 5% or
more, less than 10%Positive(+): 10% or more
Statistics
No analyses

Any other information on materials and methods incl. tables
Figures and Tables (in Japanese) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF542-18-7f.pdf
Tables (in English) are attachted to this document. Please download the export file to see the Tables.

Results and discussion
23

Test results
Key result
false
Species / strainother: Chinese hamster lung (CHL/IU) cells
Metabolic activation
with and without
Genotoxicity
negative
Cytotoxicity / choice of top concentrations
no cytotoxicity
Vehicle controls validity
valid
Untreated negative controls validity
not examined
Positive controls validity
validRemarks on result
other: strain/cell type: Chinese hamster lung (CHL/IU) cells Migrated from field 'Test system'.

Applicant's summary and conclusion
Conclusions
Interpretation of results (migrated information):negative
Chlorocyclohexane did not induce chromosomal aberrations in cultured cells.
Executive summary
An in vitro chromosomal aberration test using CHL/IU cells (OECD TG 473) was negative with or without
metabolic activation.

24

Toxicity to reproduction
Toxicity to reproduction
ENDPOINT_STUDY_RECORD: Toxicity to reproduction.001

UUID: IUC5-d811110c-8c27-46af-af04-96e78a861e27
Dossier UUID:
Author:Date: 2022-12-16T15:38:43.716+09:00
Remarks:

Administrative data
Endpoint
one-generation reproductive toxicity based on generations indicated in Effect levels (migrated information)
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition
Cross-reference
Reason / purpose for cross-reference
reference to same study
Remarks
7.5. Repeated dose toxicity: oral: Repeated dose toxicity: oral.001

Data source
Reference
A combined repeated-dose/reproductive-developmental toxicity study of chlorocyclohexane by oral
admi / MHLW (Ministry of Health, Labour and Welfare), Japan / study report
Data accessdata published

Materials and methods
25Test guideline
Qualifieraccording to guideline
Guideline
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction /Developmental Toxicity Screening Test)
Deviationsno
GLP compliance
yes
Limit test
no

Test material
Test material information
chlorocyclohexane / 542-18-7 / 208-806-6
Specific details on test material used for the study- Name of test material (as cited in study report): Chlorocyclohexane- CAS No.: 542-18-7- Molecular weight: 118.61- Lot No.: 5C1114- Purity: 99.7%- Supplier: Junsei Chemical Co., Ltd.
- Vapor pressure: 6.73 mmHg (25°C)- Vapor density : 4.12 (air = 1)
- Boiling point : 142°C- Melting point: -44°C- Flash point: 29°C
- Specific gravity: 1.004 (20/4°C)- Solubility: Insoluble in water and miscible with organic solvents such as the alcohol and ether etc.
- Odor: Peculiar odor
- Physical state: Slightly pale yellow from colorless liquid- Storage condition of test material: Dark and sealed in refrigerator (2.8 - 8.4°C)

Test animals
Speciesrat
Strain
Crj: CD(SD)rat
Sexmale/female
Details on test animals or test system and environmental conditions
TEST ANIMALS- Source: Atsugi Breeding Center, Charles River Laboratories Japan, Inc.
- Age at study initiation:9 weeks of age- Weight at study initiation: 325-386 g for males and 193-231 g for females- Housing: bracket-type metallic wire-mesh cages/males and females excluding gestation and lactat
ion periods (W 195 × D 325 × H 180 mm),26

and polycarbonate cage during gestation and lactation periods/females (W 265 × D 426 × H 200 mm)- Diet (e.g. ad libitum): ad libitum- Water (e.g. ad libitum): ad libitum excluding collected fresh urine- Acclimation period:8 days
ENVIRONMENTAL CONDITIONS- Temperature (°C):21.4 to 23.7°C- Humidity (%): 48.8 to 65.0%- Air changes (per hr): 9 to 20 times per hour
- Photoperiod (hrs dark / hrs light):12-hour lighting per day

Administration / exposure
Route of administration
oral: gavage
Vehicleolive oil
Details on exposure
PREPARATION OF DOSING SOLUTIONS: Test substance was dissolved in olive oil for injection.
VEHICLE- Justification for use and choice of vehicle: No data
- Amount of vehicle (if gavage): 5 ml/kg bw- Lot/batch no. (if required): No data
- Dosing volume: 5 mL/kg- Stability (test solutions): At least 7 days
- Storage condition of test solution: Stored in a refrigerator
Analytical verification of doses or concentrations
yes
Details on analytical verification of doses or concentrations
Test suspensions at each concentration of initial and final preparations were analyzed by the GC met
hod at Mitsubishi Safety Institute Ltd. Results showed that the concentration of the test article in eachsuspension was 95.0 to 106.2% of the nominal concentration and both values were within the acc
eptable range (concentration: percentage of the nominal concentration, 100 ± 10%)Duration of treatment / exposure(P) Males: 42 days including 14 days pre-mating and mating periods (P) Females: Days including 14
days pre-mating, mating and gestation periods and the days until day 4 of lactation
Frequency of treatment
Daily: 7 times / week
Doses / concentrations
Remarks
Doses / Concentrations:
0 (vehicle), 10, 60 and 300 mg/kg bw/day
Basis:
actual ingested
No. of animals per sex per dose
12 females/dose (0, 10, 60, 300 mg/kg), 7, 12, 12, 7 males of 0, 10, 60, 300 mg/kg, respectively, 5
males and 5 females at 0 and 300 mg/kg bw/day (recovery group)
Control animals
yes, concurrent vehicle27

Details on study design- Dose selection rationale: A preliminary study was conducted to determine the doses to be employed.
Three males and three female SD rats were receiving 0, 30, 100, 300, and 1000 mg/kg groups ofthe substance were administered for 14 days. As a result, death or dying was observed in all males
and females receiving 1000 mg/kg groups. Salivation and increases in absolute and relative adrenal
weights were observed in females receiving 300 mg/kg group. No clear changes related to the test
substance were observed in males receiving 300 mg/kg group. Therefore, the high dose was set at
300 mg/kg/day, and the middle and low dose were set at 60 and 10 mg/kg/day using common ratio
5. Vehicle control groups were set using olive oil only.

Examinations
Parental animals: Observations and examinations
CAGE SIDE OBSERVATIONS: Yes- Time schedule:
Males and females: once before the start of administration, two times/day during the administration
period, and once during the recovery period
DETAILED CLINICAL OBSERVATIONS: Yes- Time schedule:
Males: once before the start of administration, during the administration and recovery periods
Females: once before the start of administration, days 1, 7, 14 and 20 of gestation, and day 4 of lacta
tion
BODY WEIGHT: Yes- Time schedule for examinations:
Males in the main and recovery groups were weighed on Day 1, 8, 15, 22, 29, 36, 42, and 43 ofadministration, and males of recovery groups were weighed on Day 50 and 56. Female satellitegroups were weighted same frequencies to male recovery groups. Females in the main groups were
weighed on Day 1, 8 and 15 of administration and copulated females were weighed on Day 0, 7, 14
and 20 of gestation, and days 0 and 4 of lactation.
FOOD CONSUMPTION: Yes- Food consumption (g/day/rat) for each animal determined from the difference of the of the previous
day's feeding amount: Yes
Measurement of food consumption was conducted on all animals at the following frequencies:
Males in the main and recovery groups were measured on Day 1-8, 8-15, 15-22, 22-29, 29-36, 36-38,
43-50, and 50-52. Female satellite groups were measured on Day 1-8, 8-15, 15-22, 22-29, 29-36, 36-42,
43-50, and 50-56. Main females were measured same frequencies to body weighted days. It is notmeasured during the mating.
FOOD INTAKE: No
COMPOUND INTAKE: No
FOOD EFFICIENCY: No
WATER CONSUMPTION: No
Oestrous cyclicity (parental animals)
Vaginal smears were collected from all females in the main groups and microscopically examined
every day from the day after the start of administration until the day copulation was confirmed.
Mean estrous cycle (day) and abnormal estrous cycle animals (not 4 to 6 day in estrous cycle) were
examined by dams.
Sperm parameters (parental animals)
Parameters examined in P male parental generations: testes weight, epididymides weight
Litter observations
PARAMETERS EXAMINED:The following parameters were examined in F1 offspring: Number and sexof pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, and weight gain.
Postmortem examinations (parental animals)
SACRIFICE: The F1 pups were euthanized on PND 4 by exsanguination pentobarbital sodium ane
sthesia, intraperitoneally.
GROSS NECROPSY: Yes
28

Statistics
Parametric data such as grip strength, motor activity, body weight and gain, food consumption, urine
volume, specific gravity, Hematology, blood biochemistry, and absolute and relative organ weights
were analyzed by Bartlett’s test for homogeneity of distribution. When homogeneity was recognized,
one-way analysis of variance was performed. When a significant difference was observed, Dunnett’s
multiple comparison test was conducted for comparison between control and treated groups. If not
homogenous, analysis was performed using the Kruskal-Wallis ranking test. In consequence, if not
homogenous, Dunnett’s type mean rank sum test was conducted to compare to control and individual
treatment groups. Qualitative value as the pathological findings was analyzed by Wilcoxon test andFisher’s exact test. Urinalyses data were analyzed by Kruskal-Wallis and Dunnet’s type mean rank
test. Reproductive incidences of estrous cycle, fertility index, copulation index, delivery index, sex ratio, and external abnormalities were analysed by Fisher’s exact test. Significance level was set at 0.05
compared with the control group and among the groups.
Reproductive indices
1) Each parameter was determined by the following equations:
Mean estrus cycle, incidence of females with irregular estrus cycle, mating periods,
Copulation index (%) = (No. of copulated animals/No. of co-housed animals) × 100
Fertility index (%) = (No. of pregnant females/No. of copulated females) × 100
Gestation length, number of corpora lutea, number of implantation sites, total number of offspring,
Implantation index (%) = (No. of implantation sites/No. of corpora lutea) × 100
Delivery index (%) = (No. of females delivered liveborn pups/No. of pregnant females) × 100
Gestation index (%) = (No. of pregnant animals delivered live offspring/number of pregnant animals) ×100
Offspring viability indicesTotal number of offspring at birth, number of live offspring at birth,
Number of live pups on day 0 of lactationBirth index (%) = (Number of live pups on day 0/Number of
implantation sites) ×100
Viability index = (Number of live pups on day 4 after birth/Number of live pups born) ×100
External examination of offspring, necropsy finding
Pups weight on day 0 of lactation
Sex ratio on day 0 of lactation
Number of live pups on day 4 of lactation
Pups weight on day 4 of lactation
Sex ratio on day 4 of lactation

Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
Clinical signs
effects observed, treatment-related
Body weight and weight changes
effects observed, treatment-related
Food consumption and compound intake (if feeding study)
effects observed, treatment-related
Organ weight findings including organ / body weight ratios
effects observed, treatment-related
Gross pathological findings
effects observed, treatment-related
29

Histopathological findings: non-neoplastic
effects observed, treatment-related
Other effects
no effects observed

Reproductive function / performance (P0)
Reproductive function: oestrous cycle
no effects observed
Reproductive function: sperm measures
not examined
Reproductive performanceno effects observed

Details on results (P0)1) Estrous Cycle
There were no animals showing abnormal estrous cycles, and there were no significant differences in
the average length of the estrous cycle between the control group and any treatment group.
2) Results of Mating
There were no significant differences in the incidence of females with irregular estrus cycle, mating
period with the number of estrus and day of conceiving, copulation index, and fertility index between
the control group and any treatment groups.
3) Delivery Data and Delivery
There were no significant differences in the gestation length, number of corpora lutea, number of impl
antation sites, implantation index, and delivery index between the control group and any treatment g
roups.
GROSS PATHOLOGY
See 7.5.1 Repeated dose toxicity: oral
HISTOPATHOLOGY
See 7.5.1 Repeated dose toxicity: oral

Effect levels (P0)
Key result
false
Dose descriptor
NOAEL
Effect level300

mg/kg bw/day

Sexmale/female
Basis for effect level
other: No reproductive effects up to highest dose tested

Results: F1 generation
General toxicity (F1)30

Clinical signs
no effects observed
Mortality / viability
no mortality observed
Body weight and weight changes
no effects observed
Sexual maturation
no effects observed
Organ weight findings including organ / body weight ratios
not specified
Gross pathological findings
no effects observed
Histopathological findings
not specified

Effect levels (F1)
Key result
false
Dose descriptor
NOAEL
Generation
F1
Effect level300

mg/kg bw/day

Sexmale/female
Basis for effect level
other: No developmental effects up to highest dose tested

Overall reproductive toxicity
Key result
false
Reproductive effects observed
not specified

Any other information on results incl. tables
Figures and Tables (in English) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF542-18-7d.pdf
31

Applicant's summary and conclusion
Conclusions
The NOAEL for rat reproductive and developmental toxicity was determined to be 300 mg/kg bw/day.
Executive summary
A combined repeated oral dose toxicity study and reproduction/developmental toxicity screening test
was performed according to the OECD TG 422. Male and female rats (12 animals/sex/dose) wereadministered chlorocyclohexane at 0, 10, 60, and 300 mg/kg bw/day. Males were dosed for 42 days,
including a 14 day pre-mating period and subsequent mating period. Females were dosed for up to 55
days, including 14 day pre-mating, mating, and gestation periods, and the time until lactation day 4. Fiveout of 12 males dosed at 0 and 300 mg/kg bw/day were treated as a recovery group. In addition, 5
females/dose 0 and 300 mg/kg bw/day groups were dosed for 42 days without mating and examined
after the recovery period. There were no effects on reproductive and developmental parameters at 300
mg/kg bw/day. The NOAEL for the rat reproductive/developmental toxicity of chlorocyclohexane wasdetermined to be 300 mg/kg bw/day, the highest dose tested.

32

References
Reference Substances
REFERENCE_SUBSTANCE: chlorocyclohexane
UUID: ECB5-9483ca56-6e33-4ec9-a0f4-545b621d4c14
Dossier UUID:
Author:Date: 2007-05-10T18:00:00.000+09:00
Remarks:
Reference substance namechlorocyclohexane
IUPAC namechlorocyclohexane

Inventory
Inventory number
Inventory namechlorocyclohexane
Inventory
EC Inventory
Inventory number
208-806-6
CAS number
542-18-7
Molecular formulaC6H11Cl
Description
CAS number
542-18-7

Synonyms
Synonyms
Identity
chlorocyclohexane
Identity
Cyclohexane, chloro-

33

Identity
Cyclohexane, chloro-

Molecular and structural information
Molecular formulaC6H11Cl
Molecular weight118.6045
SMILES notation
ClC1CCCCC1
InChl
InChI=1/C6H11Cl/c7-6-4-2-1-3-5-6/h6H,1-5H2
Structural formula

Related substancesGroup / category information
DSL Category: Organics

34

Test Materials
TEST_MATERIAL_INFORMATION: chlorocyclohexane /542-18-7 / 208-806-6
UUID: 12489c5c-655c-3e0c-b6cf-5f492c38624a
Dossier UUID:
Author:Date: 2022-12-12T14:33:50.898+09:00
Remarks:Namechlorocyclohexane / 542-18-7 / 208-806-6

Composition
Composition
Type
Constituent
Reference substancechlorocyclohexane / chlorocyclohexane / 542-18-7 / 208-806-6
EC number

EC name208-806-6

EC Inventory

CAS number

CAS name542-18-7
IUPAC namechlorocyclohexane

35Literatures
LITERATURE: A combined repeated-dose/reproductivedevelopmental toxicity study of chlorocyclohexane by oral
administration in rats.
UUID: 830ba0b0-26d5-37a9-8ef7-84c4a85199b0
Dossier UUID:
Author:Date: 2017-01-04T16:42:46.000+09:00
Remarks:

General information
Reference Typestudy report
Title
A combined repeated-dose/reproductive-developmental toxicity study of chlorocyclohexane by oral
administration in rats.
AuthorMHLW (Ministry of Health, Labour and Welfare), Japan
Year
2007
Bibliographic source
Japan Existing Chemical Data Base (JECDB)
Testing facility
Mitsubishi Safety Institute Ltd.
Report date
2007-01-23
Study number
B04179436

LITERATURE: In Vitro Chromosomal Aberration Test of
Chlorocyclohexane on Cultured Chinese Hamster Cells
UUID: 9d974c31-5cd8-3cff-a6ab-0ee04becc208
Dossier UUID:
Author:Date: 2017-01-04T16:43:02.000+09:00
Remarks:

General information
Reference Typestudy report
Title
In Vitro Chromosomal Aberration Test of Chlorocyclohexane on Cultured Chinese Hamster Cells
AuthorMHLW (Ministry of Health, Labour and Welfare), Japan
Year
2006
Bibliographic source
Japan Existing Chemical Data Base (JECDB)
Testing facility
Mitsubishi Safety Institute Ltd.
Report date2016-09-15
Study number
B041796

37

LITERATURE: Reverse Mutation Test ofchlorocyclohexane on Bacteria.
UUID: 04ba63b5-4aaf-38de-a757-3593a38ec717
Dossier UUID:
Author:Date: 2017-01-04T16:42:56.000+09:00
Remarks:

General information
Reference Typestudy report
Title
Reverse Mutation Test of chlorocyclohexane on Bacteria.
AuthorMHLW (Ministry of Health, Labour and Welfare), Japan
Year
2006
Bibliographic source
Japan Existing Chemical Data Base (JECDB)
Testing facility
Mitsubishi Safety Institute Ltd.
Report date
2006-09-14
Study number
B041795

38

LITERATURE: Single Dose Oral Toxicity Test of
Chlorocyclohexane in RatsUUID: 5eb44718-fca3-3d6a-ba1f-2cc869f878f5
Dossier UUID:
Author:Date: 2017-01-04T16:42:38.000+09:00
Remarks:

General information
Reference Typestudy report
Title
Single Dose Oral Toxicity Test of Chlorocyclohexane in Rats
AuthorMHLW (Ministry of Health, Labour and Welfare), Japan
Year
2007
Bibliographic source
Japan Existing Chemical Data Base (JECDB)
Testing facility
Mitsubishi Safety Institute Ltd.
Report date
2007-01-23
Study number
B04179339

Legal Entities
LEGAL_ENTITY: National Institute of Health Sciences
UUID: IUC4-b036ff75-0f3c-323b-b200-ed5f46cf5101
Dossier UUID:
Author:Date: 2022-11-07T15:49:29.000+09:00
Remarks:

General information
Legal entity nameNational Institute of Health Sciences
Remarks
Disclaimer: The contents in this document were created based on the MHLW (Ministry of Health,Labour and Welfare) peer reviewed study reports (in Japanese) in JECDB (Japan Existing Chemical
Database) at http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp. Authorship is in the Divisionof Risk Assessment, the National Institute of Health Sciences, and the contents do not reflect any official MHLW opinions or any other regulatory policies.

Address
Address 1
Tonomachi 3-25-26
Address 2
Kawasaki-ku
Postal code
210-9501
Town
KawasakiRegion / State
Kanagawa
CountryJapan
JP

Identifiers
Other IT system identifiers
IT system
LEO
ID
10767
IT systemIUCLID440

ID16558402024DIV750

41